Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer

Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer

The goal of this clinical trial is to use urine tumor DNA (utDNA) as an indicator for non-muscle invasive bladder cancer to identify patients suitable for less frequent cystoscopy surveillance.

Inclusion Criteria:

• AUA high-risk bladder cancer1
• Received induction BCG or gemcitabine/docetaxel
• Negative initial post-induction therapy assessment (negative cytology and cystoscopy +/- biopsy)

Exclusion Criteria:

• High-risk NMIBC within 3 years
• Prior induction intravesical therapy
• Variant histology
• Concurrent upper tract disease